News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
211,596 Results
Type
Article (14754)
Company Profile (14)
Press Release (123264)
Multimedia
Podcasts (68)
Webinars (5)
Section
Business (53442)
Career Advice (812)
Deals (7545)
Drug Delivery (63)
Drug Development (33725)
Employer Resources (53)
FDA (6334)
Job Trends (4133)
News (101862)
Policy (13604)
Tag
2027 Bio NC Standard (1)
2027 Genetown Standard (1)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (1)
Academia (911)
Accelerated approval (23)
ADA (7)
Adcomms (13)
Allergies (100)
Alliances (8363)
ALS (53)
Alzheimer's disease (875)
Antibody-drug conjugate (ADC) (90)
Approvals (5432)
Artificial intelligence (134)
ASCO (73)
Autoimmune disease (78)
Automation (7)
Bankruptcy (29)
Belgium (1)
Best Places to Work (3084)
BIO (12)
Biologics (2)
BIOSECURE Act (3)
Biosimilars (114)
BioSpace Insights (23)
Biotechnology (10)
Bladder cancer (43)
Brain cancer (28)
Breast cancer (156)
Cancer (1204)
Cardiovascular disease (190)
Career advice (598)
Career pathing (21)
CAR-T (55)
CDC (33)
CDMO (41)
Cell therapy (208)
Cervical cancer (20)
Clinical research (20554)
Collaboration (435)
Commercialization (2)
Company closure (1)
Compensation (117)
Complete response letters (31)
COVID-19 (1252)
CRISPR (37)
C-suite (279)
Cystic fibrosis (44)
Data (2821)
Decentralized trials (2)
Denatured (4)
Depression (45)
Dermatology (51)
Diabetes (222)
Diagnostics (1188)
Digital health (11)
Diversity (6)
Diversity, equity & inclusion (18)
Drug discovery (89)
Drug pricing (88)
Drug shortages (5)
Duchenne muscular dystrophy (194)
Earnings (11241)
Editorial (36)
Employer branding (11)
Employer resources (48)
Events (15836)
Executive appointments (239)
Eye disease (2)
FDA (6581)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (15)
Funding (418)
Gene editing (66)
Generative AI (13)
Gene therapy (337)
GLP-1 (299)
Government (1673)
Grass and pollen (4)
Guidances (112)
Healthcare (4152)
Hematology (56)
HIV (41)
Huntington's disease (26)
IgA nephropathy (63)
Immunology and inflammation (93)
Immuno-oncology (23)
Indications (92)
Infectious disease (1427)
Inflammatory bowel disease (42)
Inflation Reduction Act (7)
Influenza (60)
Intellectual property (37)
Interviews (129)
IPO (2087)
IRA (23)
Job creations (652)
Job search strategy (504)
JPM (25)
Kidney cancer (2)
Kidney disease (32)
Labor market (38)
Layoffs (156)
Leadership (16)
Legal (1333)
Licensing (8)
Liver cancer (18)
Longevity (39)
Lung cancer (120)
Lymphoma (131)
Machine learning (11)
Management (14)
Manufacturing (212)
Marketing (6)
MASH (27)
Medical device (1904)
Medtech (1935)
Mergers & acquisitions (3347)
Metabolic disorders (482)
mRNA (86)
Multiple sclerosis (95)
NASH (2)
Netherlands (1)
Neurodegenerative disease (178)
Neuropsychiatric disorders (31)
Neuroscience (1424)
Neurotech (1)
NextGen: Class of 2026 (1441)
Non-profit (1262)
Now hiring (12)
Obesity (211)
Opinion (131)
Ovarian cancer (25)
Pain (56)
Pancreatic cancer (39)
Parkinson's disease (141)
Partnered (3)
Patents (101)
Patient recruitment (219)
Patient selection (1)
Peanut (48)
People (10082)
Peptides (1)
Pharmaceutical (4)
Pharmacy benefit managers (5)
Phase 1 (5141)
Phase 2 (8600)
Phase 3 (8325)
Pipeline (3218)
Policy (118)
Postmarket research (1062)
Preclinical (1594)
Press Release (7)
Prostate cancer (79)
Psychedelics (24)
Radiopharmaceuticals (84)
Rare diseases (574)
Real estate (728)
Recruiting (18)
Regulatory (7001)
Reports (22)
Research institute (710)
Resumes & cover letters (117)
Rett syndrome (35)
RNA editing (2)
RSV (73)
Schizophrenia (47)
Series A (65)
Series B (52)
Service/supplier (1)
Sickle cell disease (54)
Special edition (9)
Spinal muscular atrophy (135)
Sponsored (11)
Startups (793)
Stomach cancer (3)
Substance use disorders (6)
Supply chain (31)
Tariffs (41)
The Weekly (52)
Vaccines (644)
Venture capital (61)
Weight loss (131)
Wet AMD (1)
Women's health (46)
Worklife (8)
Date
Today (42)
Last 7 days (121)
Last 30 days (707)
Last 365 days (9477)
2026 (6843)
2025 (9902)
2024 (11432)
2023 (12786)
2022 (12567)
2021 (13197)
2020 (18034)
2019 (9905)
2018 (7364)
2017 (9907)
2016 (6448)
2015 (7279)
2014 (7556)
2013 (3931)
2012 (4074)
2011 (6460)
2010 (5839)
Location
Africa (230)
Alabama (11)
Alaska (1)
Arizona (49)
Arkansas (1)
Asia (7882)
Australia (1598)
California (2728)
Canada (636)
China (331)
Colorado (103)
Connecticut (105)
Delaware (122)
Europe (27355)
Florida (496)
Georgia (119)
Hawaii (3)
Idaho (8)
Illinois (250)
India (33)
Indiana (138)
Iowa (2)
Japan (219)
Kansas (53)
Kentucky (12)
Louisiana (15)
Maine (5)
Maryland (361)
Massachusetts (2186)
Michigan (55)
Minnesota (75)
Missouri (52)
Montana (1)
Nebraska (5)
Nevada (40)
New Hampshire (18)
New Jersey (1063)
New Mexico (7)
New York (770)
North Carolina (361)
Northern California (1415)
Ohio (48)
Oklahoma (2)
Oregon (5)
Pennsylvania (598)
Puerto Rico (2)
Rhode Island (6)
South America (262)
South Carolina (12)
South Dakota (1)
Southern California (1036)
Tennessee (46)
Texas (309)
United States (10188)
Utah (49)
Virginia (45)
Washington D.C. (22)
Washington State (204)
Wisconsin (21)
211,596 Results for "novartis ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
Novartis is the current radiopharma leader with two FDA-approved therapies in Pluvicto and Lutathera.
September 23, 2026
·
2 min read
·
Tristan Manalac
Clinical research
Novartis drags peers down with triple asset stumble
Novartis’ shares fell 13% this week after the report of three separate late-stage asset setbacks. The impact went beyond the Swiss drugmaker, dragging peers down across the market.
September 11, 2026
·
1 min read
·
Annalee Armstrong
Neuroscience
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
Novartis stands alongside Big Pharma peers that have similarly invested in technologies to penetrate the blood-brain barrier, including GSK, Roche and Eli Lilly.
September 17, 2026
·
2 min read
·
Tristan Manalac
Editorial
After Novartis’ devastating M&A losses, long live the executive willing to try
Big Pharma needs more—not fewer—bold bets on rare and difficult diseases after Novartis’ efforts to invest in muscular dystrophy and ALS hit major roadblocks this month.
September 17, 2026
·
2 min read
·
Annalee Armstrong
Job Trends
Novartis slashes New Jersey workforce again, cutting 322 employees
With the latest layoffs, Novartis expects to let go of around 800 employees by the end of 2028. More than half of the cuts have been at the company’s East Hanover, New Jersey, location.
July 7, 2026
·
1 min read
·
Angela Gabriel
C-suite
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.
September 11, 2026
·
5 min read
·
Nick Paul Taylor
Multiple sclerosis
Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle
Novartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it just behind Roche’s own BTK inhibitor fenebrutinib.
September 2, 2026
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
The failure of Novartis’ pelacarsen to translate its Lp(a)-lowering effects to clinical benefits “marks a meaningful setback” for other companies taking a similar approach to cardiovascular risk, analysts say—including Eli Lilly and Amgen.
September 8, 2026
·
2 min read
·
Tristan Manalac
Neuroscience
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
While Novartis’ antibody-oligonucleotide conjugate failed to significantly improve hand function in patients with myotonic dystrophy type 1, the asset nevertheless showed signs of clinical activity in secondary and exploratory measures.
September 8, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency
While Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate believing a competing product can make the supply chain more resilient.
August 25, 2026
·
4 min read
·
Nick Paul Taylor
1 of 21,160
Next
